BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
286.21
+1.80 (+0.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close284.41
Open284.29
Bid285.50 x 800
Ask290.00 x 800
Day's Range284.28 - 289.58
52 Week Range244.28 - 370.57
Volume1,126,515
Avg. Volume1,758,760
Market Cap60.393B
Beta1.13
PE Ratio (TTM)20.46
EPS (TTM)13.99
Earnings DateJul 23, 2018 - Jul 27, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est350.04
Trade prices are not sourced from all markets
  • Cramer Remix: The one thing that’s keeping the market fro...
    CNBC Videos15 days ago

    Cramer Remix: The one thing that’s keeping the market fro...

    Jim Cramer thinks lack of trust in the oil futures could hold the key to this market.

  • What Analysts Think about Ionis
    Market Realist16 hours ago

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.

  • How Ionis’s Spinraza Did in Q1
    Market Realist18 hours ago

    How Ionis’s Spinraza Did in Q1

    Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is an FDA-approved drug designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease in pediatric patients and adults. Biogen (BIIB), which has held the worldwide development and commercialization rights for Spinraza since January 2012, forwards royalties to Ionis.

  • Analyzing Ionis’s Q1 Revenue Streams
    Market Realist19 hours ago

    Analyzing Ionis’s Q1 Revenue Streams

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% YoY (year-over-year) to $144.4 million from $145.3 million. Analysts expect its revenue to grow 30.2% YoY to $135.7 million in the second quarter. The graph below compares Ionis’s revenue since Q1 2017.

  • What Drove Ionis’s Revenue in Q1
    Market Realistyesterday

    What Drove Ionis’s Revenue in Q1

    In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.

  • ETF Trends2 days ago

    Will “Right to Try” Bill Boost Biotech ETFs?

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, and other biotechnology assets traded slightly higher Wednesday after the U.S. House of Representatives on Tuesday passed “right to try” legislation. IBB tracks the Nasdaq Biotechnology Index and holds nearly 160 stocks.

  • InvestorPlace2 days ago

    3 Top Biosimilars that Will Lift Pfizer Inc. Stock Even More

    A month ago, Pfizer Inc. (NYSE:PFE) felt the sting of a somewhat surprising disappointment. Its biosimilar version of Herceptin, the popular breast cancer drug from Roche Holding AG (OTCMKTS:RHHBY), was rejected by the FDA.Biosimilar drugs are nearly-identical copies of a competitor’s product. It was a blow not just because Herceptin generated sales of more than $7 billion last year, but because it put the viability of Pfizer’s entire biosimilar program into question.

  • Mass. biotechs Kiniksa, Scholar Rock snag combined $228M in IPOs
    American City Business Journals2 days ago

    Mass. biotechs Kiniksa, Scholar Rock snag combined $228M in IPOs

    Nine drug developers based in Massachusetts have now gone public in the first half of 2018, raising a total of $910 million. By comparison, 12 local biotechs held IPOs in all of last year, generating around $1 billion in proceeds.

  • 3 Big Pharma Stocks with Huge Future Growth Potential
    InvestorPlace2 days ago

    3 Big Pharma Stocks with Huge Future Growth Potential

    You might not be aware of it, but big pharma stocks have gone through a difficult period for many years. A lot of the big drugs at the big pharma stocks went off patent, and the revenue for some of the big pharma stocks has fallen off as a result. Some of the big pharma stocks were able to replace that revenue and some weren’t.

  • Why is Biogen (BIIB) Up 6.7% Since Its Last Earnings Report?
    Zacks2 days ago

    Why is Biogen (BIIB) Up 6.7% Since Its Last Earnings Report?

    Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene
    Investor's Business Daily3 days ago

    Why Amgen's In Trouble — And Should Take Notes From Biogen, Celgene

    Amgen trades at a premium to biotech companies Celgene and Biogen, but analysts are worried its pipeline contains fewer blockbuster opportunities.

  • Vivus Stock Rose 60% Last Week
    Market Realist4 days ago

    Vivus Stock Rose 60% Last Week

    Vivus (VVUS) rose 60% between May 11 and May 18. Headquartered in Cambell, California, Vivus is a fast-growing healthcare company focused on the development of innovative therapies for obesity, sexual health, and sleep. In May 2018, Vivus entered an agreement with Johnson & Johnson (JNJ) to acquire all product rights of Janssen Pharmaceuticals’ Pancreaze in the United States.

  • Better Buy: Acadia Pharmaceuticals vs. Biogen
    Motley Fool7 days ago

    Better Buy: Acadia Pharmaceuticals vs. Biogen

    Which of these beaten-down biotech stocks is in better position to mount a strong comeback?

  • Amgen Stock Rises over 2% on Drug Approvals
    Market Realist8 days ago

    Amgen Stock Rises over 2% on Drug Approvals

    On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.

  • BlueBird Bio Stock Jumps over 6% on May 17
    Market Realist8 days ago

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio (BLUE) is a biotechnology company focused on developing gene therapy, cancer immunotherapy, and gene editing for the treatment of serious diseases. On May 17, Bluebird Bio (BLUE) stock jumped over 6.1% to the closing price of $189.30 per share, following positive news.

  • Reuters8 days ago

    Samsung BioLogics said JV partner Biogen to exercise option by late June

    South Korean drugmaker Samsung BioLogics said on Friday joint venture partner Biogen would exercise its call option to increase its stake to 50 percent minus one share in Samsung Bioepis. The plan comes as BioLogics is mired in a regulatory probe into its accounting rules. South Korea's financial regulator said it notified BioLogics, an affiliate of tech giant Samsung Electronics , of measures it could take concerning any breach of accounting rules.

  • Biogen, Shire called out by FDA for ‘gaming’ generic access rule
    American City Business Journals9 days ago

    Biogen, Shire called out by FDA for ‘gaming’ generic access rule

    The FDA’s decision to publish a list of companies accused of blocking access to their product samples is part of a broader effort by the Trump administration to address high drug costs.

  • MarketWatch11 days ago

    Your guide to the Trump drug price plan: who it affects and how

    President Donald Trump’s new plan, “American Patients First,” is supposed to make U.S. drug prices cheaper. For some players, there could be long-term concerns, including for pharmacy-benefit managers and other drug system middlemen. This was partly because many of the ideas in the plan had been raised by the Trump administration prior to the speech, including in a proposed 2019 budget.

  • Better Buy: Amgen Inc. vs. Biogen Inc.
    Motley Fool11 days ago

    Better Buy: Amgen Inc. vs. Biogen Inc.

    Find out which biotech stock stands tallest after a head-to-head matchup.

  • Biogen Inc (NASDAQ:BIIB): Does The Earnings Decline Make It An Underperformer?
    Simply Wall St.11 days ago

    Biogen Inc (NASDAQ:BIIB): Does The Earnings Decline Make It An Underperformer?

    Today I will examine Biogen Inc’s (NASDAQ:BIIB) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, in addition to howRead More...

  • Associated Press14 days ago

    Biogen and American Express rise; Symantec plunges

    Stocks that moved substantially or traded heavily on Friday: Symantec Corp., down $9.66 to $19.52 The security software maker gave weak forecasts and disclosed an internal investigation. Yelp Inc., down ...

  • 6 Ways To Play Biotechs As Small Stocks Score Big Gains
    Investor's Business Daily14 days ago

    6 Ways To Play Biotechs As Small Stocks Score Big Gains

    The biotech group is trying to climb past its 50-day moving average, so it may be a good time to keep an eye on biotech ETFs.

  • TheStreet.com14 days ago

    Biogen Is Set for a Tradable Rally

    In this daily bar chart, below, we can see that BIIB has rallied above the bottoming 50-day moving average line. The daily On-Balance-Volume (OBV) line has been moving sideways since early March even though prices were still declining into late April. In the bottom panel of this chart we can see a bullish divergence as momentum makes higher lows from February while prices made lower lows.

  • Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects
    CNBC15 days ago

    Cramer vets biotech giants Biogen, Celgene, Gilead and Regeneron for positive prospects

    Jim Cramer examines "the four horsemen of biotech" to see if their weakening stocks can regain momentum.